Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2012
10/11/2012US20120258112 Antibodies against human ccn1 and uses thereof
10/11/2012US20120258111 Compositions and methods for modulating rsv infection and immunity
10/11/2012US20120258110 Fdf03 antibodies and uses thereof
10/11/2012US20120258109 Antibodies that bind tgf-alpha and epiregulin
10/11/2012US20120258108 Dual Variable Domain Immunoglobulins and Uses Thereof
10/11/2012US20120258107 Agents, Uses and Methods
10/11/2012US20120258106 Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
10/11/2012US20120258105 Methods and compositions to regulate iron metabolism
10/11/2012US20120258104 Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
10/11/2012US20120258103 Compounds and methods for the treatment of renal disease
10/11/2012US20120258102 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibodies
10/11/2012US20120258101 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
10/11/2012US20120258100 Chimeric anti-ricin antibody
10/11/2012US20120258099 Inhibitors of guanine exchange factors and their use as anticancer drugs
10/11/2012US20120258098 Method of Treating Rheumatoid Arthritis with an Anti-IL-6R Antibody
10/11/2012US20120258097 Methods of using btl-ii proteins
10/11/2012US20120258096 Anti-d monoclonal antibodies
10/11/2012US20120258095 Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
10/11/2012US20120258094 Method for treating a rheumatic disease using a soluble ctla4 molecule
10/11/2012US20120258093 Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
10/11/2012US20120258092 Optimized Fc Variants
10/11/2012US20120258091 Genetic products differentially expressed in tumors and the use thereof
10/11/2012US20120258080 Pyridopyrazine derivatives and their use
10/11/2012US20120258079 Treatment and Prevention of Dengue Virus Infections
10/11/2012US20120258078 Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis c
10/11/2012US20120258077 Human M2e Peptide Immunogens
10/11/2012US20120258073 Immunotherapy
10/11/2012US20120258045 Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
10/11/2012US20120258042 Combined use of tgf-b signaling inhibitor and antitumor agent
10/11/2012US20120258041 Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
10/11/2012US20120258040 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
10/11/2012US20120258039 Treatment of tumors using specific anti-l1 antibody
10/11/2012DE102011006809A1 Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten Use of an agent consisting of antibodies and / or insulin-like growth factor antagonists
10/11/2012DE102011006781A1 Antikörperprodukt, umfassend n spezifische Antikörper Antibody product comprising n-specific antibodies
10/11/2012CA2834734A1 Methods of improving vaccine immunogenicity
10/11/2012CA2833425A1 Protease cleavage site peptides as an hiv vaccine
10/11/2012CA2832738A1 Herpes simplex virus
10/11/2012CA2832735A1 Method of inducing neutralizing antibodies to human immunodeficiency virus
10/11/2012CA2832665A1 Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method
10/11/2012CA2832556A1 Formulations with reduced viscosity
10/11/2012CA2832373A1 Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
10/11/2012CA2832281A1 Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
10/11/2012CA2832260A1 Method for treating ifnalpha related conditions
10/11/2012CA2832187A1 Methods for treating conditions associated with masp-2 dependent complement activation
10/11/2012CA2832148A1 Peptide which can induce antibody capable of recognizing stereostructure of hiv
10/11/2012CA2832106A1 Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
10/11/2012CA2830820A1 Process for producing an immunogenic composition containing tetanus toxoid
10/11/2012CA2830013A1 Recombinant polypeptide production method
10/11/2012CA2828890A1 Anti-fgfr4 antibodies and methods of use
10/10/2012EP2508601A2 Tem8 peptides and vaccines comprising the same
10/10/2012EP2508596A2 MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
10/10/2012EP2508536A1 Cytotoxicity mediation of cells evidencing surface expression of CD44
10/10/2012EP2508203A1 PRRSV GP5 based compositions and methods
10/10/2012EP2508202A1 Non-replicative virions of human immunodeficiency virus and therapeutic applications thereof
10/10/2012EP2508201A1 Method for the identification of animals vaccinated against brucella
10/10/2012EP2508200A1 Carbonic anhydrase i serving as novel antigen to be used for treatment of autoimmune diseases
10/10/2012EP2508197A1 Method for treating IFNalpha related conditions
10/10/2012EP2507263A1 Anti-igf-ir antibodies and uses thereof
10/10/2012EP2507262A1 Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
10/10/2012EP2507259A1 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins
10/10/2012EP2507257A1 Mybl2 peptides and vaccines containing the same
10/10/2012EP2507256A1 Imp-3 oligopeptides and vaccines including the same
10/10/2012EP2506881A1 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
10/10/2012EP2506877A1 Therapies for preventing or suppressing clostridium difficile infection
10/10/2012EP2506875A1 Methods for treating cancers comprising k-ras mutations
10/10/2012EP2506874A1 Von willebrand factor specific binding agents and uses thereof
10/10/2012EP2506873A2 Vaccine against neoplastic or cancerous lesions caused by human papillomavirus (hpv), procedures, uses and methods
10/10/2012EP2506872A1 Inactivated poultry vaccine
10/10/2012EP2506871A1 ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
10/10/2012EP2506870A1 Prostate cancer dna vaccine
10/10/2012EP2506864A1 Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
10/10/2012EP2506834A2 Circulation of components during microfluidization and/or homogenization of emulsions
10/10/2012EP2506833A2 Arranging interaction and back pressure chambers for microfluidization
10/10/2012EP2506832A2 Hydrophilic filtration during manufacture of vaccine adjuvants
10/10/2012CN1997390B Microfluidized oil-in-water emulsions and vaccine compositions
10/10/2012CN1976718B Vaccine against HPV 16 and HPV 18 and at least another HPV type selected from HPV 31, 45 or 52
10/10/2012CN1973053B Novel anti-IL 13 antibodies and uses thereof
10/10/2012CN1694902B Antibody binding with epitope of EphB4 polypeptides and application thereof
10/10/2012CN1678188B Nucleic acid compositions for stimulating immune responses
10/10/2012CN1662251B Adjuvant enhanced immunotherapy
10/10/2012CN1522156B Novel engineered superantigen for human therapy
10/10/2012CN1452496B Use of strains of parapox ovis virus against organ fibrosis
10/10/2012CN1371416B Human CTLA-4 antibodies and their uses
10/10/2012CN1359301B Pharmaceutical composition comprising antibody specifically binding epitope in A-beta-10 residual group and its application
10/10/2012CN102725310A Isoform specific anti-HER4 antibodies
10/10/2012CN102725000A Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (IGF-1R)
10/10/2012CN102724999A Therapeutic agent for psoriasis or atopic dermatitis
10/10/2012CN102724998A Vaccine having a peptide adjuvant for eliciting a specific immune response to treat viral infection and other conditions
10/10/2012CN102724997A Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
10/10/2012CN102724996A Inhibitors of vascular endothelial growth factor (VEGF) receptors and methods of use thereof
10/10/2012CN102724984A Enterococcal cell wall components and antibacterial use thereof
10/10/2012CN102724973A Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms
10/10/2012CN102719521A Application of cystine/glutamic acid reverse transporter xCT inhibitor in treating liver cancer
10/10/2012CN102719478A Chimpanzee adenovirus vaccine carriers
10/10/2012CN102719466A Recombinant plasmid and subunit vaccine of extracellular protease recombinant protein of Aeromonas hydrophila prepared from same plasmid
10/10/2012CN102719453A Human papilloma virus 18 L1 (HPV18L1) polynucleotide sequence and its expression vector, host cell and use
10/10/2012CN102719443A Carboxyl-terminal specific anti-human amyloid protein monoclonal antibody gene and its encoded polypeptide and application
10/10/2012CN102719441A Preparation method of antibody of trichina antigen gene TS498 associated to breast cancer
10/10/2012CN102719408A Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
10/10/2012CN102719407A Porcine parvovirus BQ-C strain and application of porcine parvovirus BQ-C strain to preparation of inactivated porcine parvovirus vaccine
1 ... 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 ... 1823